Orchestra BioMed Holdings, Inc.
HealthcareNASDAQ:OBIO · NASDAQ Global Market
+$0.03 today
Vol 0.54M · Avg 0.21M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$32.7M of revenue converted into -$54.6M of net income for the selected period. Gross margin is 76.3% and net margin is -5881.2%, showing how much revenue survives after costs and taxes. EPS is $-1.42, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $33.5M +1169.2% | $2.6M -4.4% | $2.8M -21.9% | $3.5M +551.8% | -$782.0K | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $190.0K -6.9% | $204.0K +9.7% | $186.0K -42.2% | $322.0K +61.8% | $199.0K | $725.6M | $804.0M | $882.4M |
| Gross Profit | $33.3M +1267.8% | $2.4M -5.4% | $2.6M -19.8% | $3.2M +427.3% | -$981.0K | $8.9B | $7.6B | $6.2B |
| Gross Margin | 99.4% +7.2pp | 92.3% -1.0pp | 93.3% +2.4pp | 90.9% -34.6pp | 125.4% | 9.8% | 28.9% | 38.3% |
| Research & Development | $58.2M +35.9% | $42.8M +26.6% | $33.8M +54.1% | $21.9M +70.2% | $12.9M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $26.9M +12.5% | $23.9M +18.1% | $20.3M +45.5% | $13.9M +75.6% | $7.9M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $85.1M +27.5% | $66.7M +23.4% | $54.1M +50.8% | $35.9M +72.3% | $20.8M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $327.0K +6.2% | $308.0K +7.3% | $287.0K +29.3% | $222.0K +22.7% | $181.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$51.2M +15.6% | -$60.7M -24.3% | -$48.8M -46.3% | -$33.4M -52.4% | -$21.9M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -153.0% +2148.6pp | -2301.6% -532.3pp | -1769.3% -824.3pp | -945.0% -3746.3pp | 2801.3% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$51.8M +19.4% | -$64.3M -24.8% | -$51.5M -57.7% | -$32.7M -49.8% | -$21.8M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -154.7% +2282.8pp | -2437.5% -571.3pp | -1866.2% -941.8pp | -924.3% -3711.9pp | 2787.6% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 -100.0% | $3.4M -12.8% | $3.8M +7598.0% | $50.0K | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $1.1M | $0 | $0 | $0 -100.0% | $927.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$894.0K -127.3% | $3.3M +37.3% | $2.4M +350.9% | -$951.0K +21.7% | -$1.2M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$52.7M +13.6% | -$61.0M -24.2% | -$49.1M -46.2% | -$33.6M -46.0% | -$23.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -157.4% +2155.9pp | -2313.3% -533.6pp | -1779.7% -828.5pp | -951.3% -3894.2pp | 2943.0% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$52.7M +13.6% | -$61.0M -24.2% | -$49.1M -46.2% | -$33.6M -46.0% | -$23.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | -157.4% +2155.9pp | -2313.3% -533.6pp | -1779.7% -828.5pp | -951.3% -3894.2pp | 2943.0% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +16.9% | -$2 -12.2% | -$1 -12.1% | -$1 -7035.1% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +16.9% | -$2 -12.2% | -$1 -12.1% | -$1 -7035.1% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $38.4M +4.3% | $36.8M +10.8% | $33.2M +30.4% | $25.5M +24.6% | $20.4M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $38.4M +4.3% | $36.8M +10.8% | $33.2M +30.4% | $25.5M +24.6% | $20.4M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Prelude Therapeutics Incorporated
NASDAQ:PRLD
$352.45M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$276.28M
Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRX
$202.22M
Inventiva S.A.
NASDAQ:IVA
$200.13M
Avalo Therapeutics, Inc.
NASDAQ:AVTX
$166.70M
Caribou Biosciences, Inc.
NASDAQ:CRBU
$158.19M
Protara Therapeutics, Inc.
NASDAQ:TARA
$150.50M
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
$118.59M
Pyxis Oncology, Inc.
NASDAQ:PYXS
$111.51M
Invivyd, Inc.
NASDAQ:IVVD
$102.20M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does OBIO generate?
Orchestra BioMed Holdings, Inc. (OBIO) reported $33.48M of revenue in fiscal 2025.
Is OBIO profitable?
Orchestra BioMed Holdings, Inc. (OBIO) reported -$52,701,000.00 of net income, with a net margin of -157.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.